



French Hospital Database on HIV (FHDH)

ANRS-CO4 FHDH

Investigateur principal : Dominique Costagliola

Co-investigateur principal : Sophie Grabar

**Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de
Santé Publique (IPLESP UMRS 1136)**

References

Before 1999

1. Guiguet M, Mary M, Costagliola D, Armengaud M, Cartier F, Micoud M, Mouton Y, Sobesky G, Valleron AJ. Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals. *AIDS* 1992;6(11):1405-6.
2. Costagliola D, Mary-Krause M. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficiency Humaine. *Lancet* 1995;346(8974):578.
3. Mikol J, Costagliola D, Polivka M, Thiebaut JB, Trotot P. [The epidemiology of cerebral lymphoma in AIDS]. *J Neuroradiol* 1995;22(3):204-6.
4. Salhi Y, Costagliola D. Long-term nonprogression in HIV infection. Clinical Epidemiology Group from the Centre d'Information et de Soins de l'Immunodeficiency Humaine. *J Acquir Immune Defic Syndr Hum Retrovirol* 1997;16(5):409-11.
5. Le Moing V, Bissuel F, Costagliola D, Eid Z, Chapuis F, Molina JM, Salmon-Ceron D, Brasseur P, Leport C. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. *AIDS* 1998;12(11):1395-7.
6. Ray P, Antoine M, Mary-Krause M, Lebrete MG, Wislez M, Duvivier C, Meyohas MC, Girard PM, Mayaud C, Cadranet J. AIDS-related primary pulmonary lymphoma. *Am J Respir Crit Care Med* 1998;158(4):1221-9.
7. Roux P, Ha MC, Brucker G, Costagliola D. Pneumocystis and pneumocystosis in Europe at the end of the 20th century. *FEMS Immunol Med Microbiol* 1998;22(1-2):87-91.

1999

8. Lievre L, Meyohas MC, Costagliola D. Impact of opportunistic diseases on survival in HIV-infected patients in France, 1992-1997. Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficiency Humaine. *AIDS* 1999;13(13):1789-90.
9. Mary-Krause M, Billaud E. Impact of Kaposi's sarcoma in occurrence of opportunistic central nervous system disease. Clinical Epidemiology Group. *AIDS* 1999;13(14):1985-7.
10. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. *AIDS* 1999;13(15):2075-82.
11. Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, Costagliola D. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. *AIDS* 1999;13(14):1881-7.

2000

12. Bernillon P, Lievre L, Pillonel J, Laporte A, Costagliola D. Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficiency Humaine. *Int J Epidemiol* 2000;29(1):168-74.
13. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. *Ann Intern Med* 2000;133(6):401-10.
14. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. *AIDS* 2000;14(2):141-9.
15. Mary-Krause M, Rabaud C, Jouan M, Obadia M, de la Blanchardiere A, Raffi F, May T. [Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency]. *Pathol Biol (Paris)* 2000;48(5):495-504.

2001

16. Abgrall S, Matheron S, Le Moing V, Dupont C, Costagliola D. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis. *J Acquir Immune Defic Syndr* 2001;26(2):151-8.
17. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. *Clin Infect Dis* 2001;33(10):1747-55.
18. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, Katlama C, Charlotte F, Dupont B, Brousse N, Huerre M, Mikol J, Camparo P, Mokhtari K, Tulliez M, Salmon-Ceron D, Boue F, Costagliola D, Raphael M. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. *Blood* 2001;98(8):2339-44.

2002

19. del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. *J Infect Dis* 2002;186(9):1366-70.
20. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360(9327):119-29.
21. Tassie JM, Grabar S, Lancar R, Deloumeaux J, Bentata M, Costagliola D. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. *J Acquir Immune Defic Syndr* 2002;30(1):81-7.

2003

22. Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. *Clin Infect Dis* 2003;37(11):1517-26.
23. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. *Lancet* 2003;362(9385):679-86.
24. Herida M, Mary-Krause M, Kaphan R, Cadranet J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. *J Clin Oncol* 2003;21(18):3447-53.
25. Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2003;34(1):50-7.
26. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *Aids* 2003;17(17):2479-86.

2004

27. Grabar S, Kousignian I, Sobel A, Lebras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D. Immunologic and clinical responses to HAART over 50 years of age. Results from the French Hospital Database on HIV. *Aids* 2004; 18(15):2029-2038.
28. Mary-Krause M, Herida M, Costagliola D, Lavole A, Cadranet J. In reply. *J Clin Oncol* 2004;22(7):1349-50.
29. May M, Royston P, Egger M, Justice AC, Sterne JAC and the ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. *Statistics in Medicine* 2004; 23: 2375-98

30. Phillips A, Ledergerber B, Lundgren J, Hogg B, D'Arminio Monforte A, Castelli F, Walker S, Staszewski S, Dabis F, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fischer M, Mussini C, Klein M, Costagliola D for the Collaboration of HIV Cohorts. Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound. *J Infect Dis* 2004;190(4):675-687.

2005

31. The ART Cohort collaboration (d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M). The Changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. *Arch Intern Med* 2005 ; 165(4):416-423
32. Costagliola D, Potard V, Duvivier C, Pradier C, Dupont C, Salmon D, Duval X for the French Hospital Database on HIV. Impact of newly available drugs on clinical progression in patients with virologic failure after exposure to three classes of antiretrovirals. *Antivir Ther* 2005; 10(4):563-573.
33. Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill JM, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JAC. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. *Clin Infect Dis* 2005; 41(12): 1772-1782.
34. Grabar S, Le Moing V, Goujard C, Egger M, Lepout C, Kazatchkine M, Weiss L, Costagliola D. Response to HAART at 6 months and long-term disease progression in HIV-1 infection. *J Acquir Immune Defic Syndr* 2005; 39(3):284-292.
35. May M, Porter K, Sterne JAC, Royston P, Egger M, The Antiretroviral Therapy Cohort Collaboration and CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe). Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. *Journal of Clinical Epidemiology* 2005; 58: 1033-1041
36. Sabin CA, Hogg B, Dabis F, Gill JM, Phillips AN, Reiss P, Fätkenheuer G, Grabar S, Lundgren J, Justice A, Ledergerber B, d'Arminio Monforte A, Staszewski S, Sterne JAC. Clinical AIDS events following initiation of HAART: do some patients experience a greater benefit from HAART than others ? *AIDS* 2005; 19(17): 1995-2000.

2006

37. Abgrall S, Yeni PG, Bouchaud O, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database on HIV. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. *AIDS* 2006; 20(16): 2099-2106.
38. Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg D, Balestre E, Sterne J, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and the ART Cohort Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 2006; 367: 817-824.
39. Fardet L, Mary-Krause M, Heard I, Partisani ML, Costagliola D for the French Hospital Database on HIV. Influence of gender and HIV transmission group on initial HAART prescription and treatment response. *HIV Med* 2006; 7(8): 520-529.
40. Fontaine C, Bonnard P, Mary-Krause M, Callard P, Pialoux G. Pulmonary pneumocystosis in a patient with greater than 500 CD4 cells/mul: a role for IL-2 therapy? *AIDS* 2006; 20(12): 1680-1681.
41. Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. *J Clin Oncol* 2006; 24(21): 3408-3414.
42. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. *J Antimicrob Chemoth* 2006; 57(1): 4-7.
43. Hernán MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. *Basic Clin Pharmacol Toxicol* 2006; 98(3): 237-242.

44. Hogg R, May M, Phillips A, Costagliola D, Sterne J, Sabin C, De Wolf F, Ledergerber B, D'Arminio Monforte A, Justice A, Gill J, Fusco G, Staszewski S, Rockstroh J, Chêne G, Egger M. Rates of disease progression according to initial HAART regimen A collaborative analysis of 12 prospective cohort studies. *J Infect Dis* 2006; 194(5): 612-622.
45. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D and the Clinical Epidemiology Group of the French Hospital Database on HIV infection. Predictors identified for losses to follow-up among HIV-seropositive patients. *J Clin Epidemiol* 2006; 59(8): 829-835.
46. Lewden C, Jouglu E, Alioum A, Pavillon G, Lièvre L, Morlat P, Salmon D, May T, G Chêne G, Costagliola D and the Mortalité 2000 Study Group. Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. *Epidemiol Infect* 2006; 134(6): 1353-1359.
47. Lievre L, Deveau C, Gerbe J, Enel P, Tran L, De Castro N, Costagliola D, Meyer L, the Primo Study Group, and the Clinical Epidemiology Group of the French Hospital Database on HIV. Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. *AIDS* 2006; 20(18): 2392-2395.
48. Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudière L, Costagliola D. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy (cART). *AIDS* 2006; 20(12):1627-1635.
49. May MT, Sterne JAC, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. *Lancet* 2006; 368: 451-458.

2007

50. Abgrall S, Yeni PG, Bouchaud O, Costagliola D, and the Clinical Epidemiology Group of the French Hospital Database on HIV. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first PI-containing antiretroviral combination to a three-drug regimen containing efavirenz, nevirapine or abacavir. *Clin Inf Dis* 2007; 44(1): 120-127.
51. Brinkhof MWG, Egger M, Boule A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg D, Rickenbach M, Meda JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, Van der Borgh, Schechter M and the ART-LINC Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA) and the ART Cohort Collaboration. Tuberculosis following initiation of antiretroviral therapy in low-income and high-income countries. *Clinical Infectious Diseases* 2007; 45: 1518-21.
52. Guiguet M, Furco A, Tattevin P, Costagliola D, Molina JM, and the French Hospital Database on HIV Clinical Epidemiology Group. HIV-associated *Isospora belli* infection: incidence and risk factors in the French Hospital Database on HIV. *HIV Med* 2007; 8(2): 124-130.
53. Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, Costagliola D and ANRS CO04 French Hospital Database on HIV Clinical Epidemiological Group. Frequency, determinants and consequences of delayed access to care for HIV infection in France. *Antivir Ther* 2007; 12(1): 89-96.
54. May M, Sterne JAC, Sabin C, Costagliola D, Justice AC, Thiébaud R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1 infected patients up to five years after initiation of HAART: collaborative analysis of prospective studies. *AIDS* 2007; 21(9): 1185-1197.
55. Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D. First-line HAART regimens in 2001-2002 in the French Hospital Database on HIV: Combination prescribed and biological outcomes. *Antivir Ther* 2007; 12(3): 317-324.
56. Sterne JA, May MT, Sabin CA, Phillips AN, Costagliola D, Chene G, Justice AC, de Wolf F, Hogg RS, Battegay M, d'Arminio Monforte A, Fätkenheuer G, Staszewski S, Gill JM, Egger M for the Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: Collaborative analysis of cohorts of HIV-1 infected patients. *J Acquir Immune Defic Syndr* 2007 ; 46(5):607-615.

2008

57. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. *JAMA*. 2008; 300(1): 51-9.
58. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. *AIDS*. 2008; 22(12): 1463-1473.
59. Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D on behalf of the Clinical Epidemiology Group of the French Hospital Database on HIV. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. *HIV Med* 2008; 9(4):246-256.
60. Guiguet M, Mary-Krause M, Ename B, Costagliola D, Grabar S. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). *Pharmacoepidemiol Drug Saf* 2008 17(5): 468-474
61. Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A, on behalf of the CASCADE Collaboration. Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). *The open AIDS journal* 2008; 2: 3-9.
62. Harris RJ, Sterne JAC, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, M Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, D'Arminio Monforte A, May M, Egger M Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries. *Antivir Ther* 2008;13(8): 959-967.
63. Hogg R, Lima V, Sterne J, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill J, Harris R, Justice A, Kitahata M, Lampe F, Mocroft A, Mugavero M, Staszewski S, Wasmuth JC, van Sighem A, Hayden A, Guest J, Egger M, May M. Life expectancy of persons on combination antiretroviral therapy (cART) in high-income countries. *Lancet*. 2008;372:293-299
64. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. *Am J Epidemiol*. 2008; 168(5):532-40.
65. Kousignian I, Abgrall S, Grabar S, Mahamat, Teicher E, Rouveix E, Costagliola D and the Clinical Epidemiology Group of the French Hospital Database on HIV. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. *Clin Infect Dis* 2008; 46:296–304.
66. Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N, Costagliola D, Matheron S. Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study. *J Acquir Immune Defic Syndr* 2008; 49(1):55-60.
67. Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Huldrych F, Günthard HF, Dabis F, Robert Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Fiona Lampe F, Miró JM, Staszewski S, Sterne JAC. Does Short-term Virologic Failure Translate to Clinical Events in ARV-naïve Patients Initiating ART in Clinical Practice? *AIDS* 2008; 22(18):2481-92.
68. Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K; CASCADE Collaboration. The effect of antiretroviral treatment of different durations in primary HIV infection. *AIDS* 2008; 22(18): 2441-50.
69. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M, on behalf of the FHDH-ANRS CO 4. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with cART. *AIDS* 2008; 22(10): 1203-1211.
70. Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S, for the Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4). Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy. *J Acquir Immune Defic Syndr* 2008; 47(2):206-211.

71. Touloumi G, Pantazis N, Stirnadel H, Walker SA, Boufassa F, Vanhems P, Porter K, on behalf of the CASCADE Collaboration. Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. *J Acquir Immune Defic Syndr* 2008; 49(5):492-498.

2009

72. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy: European multi-cohort study. *AIDS* 2009; 23(15):2029-2037.
73. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Chene G, Lundgren J, Egger M. Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study. *Antivir Ther* 2009; 14(8): 1065-74.
74. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. *AIDS* 2009; 23(6): 717-24
75. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, on behalf of the FHDH ANRS CO4 and ANRS CO14. Interleukine 2 therapy does not increase the risk of Hodgkin's or non Hodgkin's lymphoma in HIV-infected patients; results from FHDH ANRS CO4. *J Acquir Immune Defic Syndr* 2009; 50(2): 206-214.
76. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term non-progressors and HIV controller patients in the French Hospital Database on HIV. *AIDS* 2009; 23(9):1163-1169.
77. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, on behalf of the Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. *Lancet Oncology* 2009; 10: 1152-1159.
78. Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X, on behalf of the FHDH-ANRS CO4 Epidemiology Group. CD4 cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naïve patients with CD4 cell counts above 200/mm³. *Antivir Ther* 2009 ; 14(3): 451-457.
79. Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D. Observation plans in longitudinal studies with time-varying treatments. *Stat Methods Med Res* 2009; 18(1): 27-52.
80. Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D, ANRS CO4 FHDH and Groupe d'Etude Mortalité 2000. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French Hospital Database on HIV, Mortalité 2000 Survey and death certificates. *HIV Med* 2009; 10(4): 236-245.
81. Lanoy E, May M, Mocroft A, Phillips A, Justice A, Chêne G, Furrer H, Sterling T, D'Arminio Monforte A, Force L, Gill J, Harris R, Hogg RS, Kitahata M, Rockstroh J, Saag M, Staszewski S, de Wolf F, Sterne JAC, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS* 2009; 23(16):2199-2208.
82. Marin B, Thiébaud R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker AS, Porter K, Sabin C, Chêne G on behalf of the CASCADE Collaboration. Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. CASCADE, 1996-2006. *AIDS* 2009; 23(13):1743-1753
83. Mocroft A, Sterne J, Egger M, May M, Grabar S, Hansjakob Furrer H, Sabin C, Fätkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS defining events diagnosed during combination antiretroviral therapy: Not all AIDS Defining Conditions are Created Equal. *Clin Infect Dis* 2009; 48(8): 1138-1151.

84. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, J. Mugavero MJ, D'Arminio Monforte A, Sabin C, Podzamczar D, Fätkenheuer G, Staszewski S, Gill J, Sterne JAC. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. *J Acquir Immune Defic Syndr* 2009; 52(3):357-363.
85. Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S, on behalf of the FHDH-ANRS CO4 Clinical Epidemiology Group. Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350/mm³. *AIDS* 2009; 23(15): 1997-2004.
86. Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey MP, Faouzi Souala M, Costagliola D and the French hospital database on HIV, ANRS CO4 Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005. *J Acquir Immune Defic Syndr* 2009; 52(3):422-426.
87. Sterne JAC, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Jönsson Funk M, Geskus R, Gill J, Dabis F, Miró JM, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, D'Arminio Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole SR (When to start consortium). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 2009; 373(9672): 1352-1363.
88. Zwahlen M, Hogg R, May M, Costagliola D, Lewden C, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with general population in eight countries. *Int J Epidemiol* 2009; 38(6):1624-1633.

2010

89. Abgrall S, Del Giudice P, Melica G, Costagliola D, on behalf of FHDH-ANRS CO4. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. *AIDS* 2010; 24(5):763-771.
90. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernán MA. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. *Int J Biostat* 2010; 6(2): 18.
91. Colin X, Lafuma A, Costagliola D, Lang JM, Guillon P. The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France. *Pharmacoeconomics*. 2010 Dec 23;28(S1):59-68.
92. Colin X, Lafuma A, Costagliola D, Smets E, Mauskopf J, Guillon P. Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France. *Pharmacoeconomics*. 2010 Dec 23;28(S1):183-197.
93. Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, Levy Y, Costagliola D, on behalf of FHDH ANRS CO4 and ANRS CO14. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy. Results from the ANRS CO4 cohort. *J Antimicrob Chemoth* 2010; 65(10): 2215-2223.
94. Gill J, May M, Lewden C, Saag M, Mugavero M, Reiss P, Ledergerber B, Mocroft A, Harris R, Fux CA, Justice A, Costagliola D, Casabona J, Hogg RS, Khaykin P, Lampe F, Vehreschild J, Sterne JAC. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 2010; 50(10): 1387-1396.
95. Kousignian I, Launay O, Mayaud C, Rabaud C, Costagliola D, Abgrall S; on behalf of the FHDH-ANRS CO4. Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? *J Antimicrob Chemoth* 2010; 65(1):138-144.
96. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Bingham A, Costagliola D for the Clinical Epidemiology Group of the French Hospital Database on HIV. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. *AIDS* 2010; 24(8): 1228-1230.
97. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D for the Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in HIV-infected patients: a case-control study nested within the FHDH ANRS Cohort CO4. *Arch Intern Med* 2010; 170(14): 1228-1238.
98. Lodi S, Guiguet M, Costagliola D, Fisher M, De Luca A, Porter K and the CASCADE collaboration. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. *JNCI* 2010; 102(11):784-92.

99. Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K, on behalf of the Cascade Collaboration. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. *AIDS* 2010; 24(17): 2697-704.
100. Lodwick L, Costagliola D, Reiss P, Carlo Torti C, Teira R, Dorrucchi M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, García F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warszawski J, Thorne C, Masip J, Perez-Hoyos S, Tookey P, Pillay D, van Sighem A, Lo Caputo S, Günthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chene G, Lundgren J, Phillips A. Triple class virologic failure in HIV-infected patients on antiretroviral therapy for up to 10 years. *Arch Intern Med* 2010; 170(5):410-419.
101. Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *AIDS* 2010; 24: 123–137.
102. Wolbers M, Babiker A, Sabin C, Young J, Dorrucchi M, Chêne G, Mussini C, Porter K, Bucher HC; CASCADE Collaboration Members. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. *PLoS Med.* 2010; 7(2): e1000239.
103. Yazdanpanah Y, Sloan C.E, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV screening in France: Clinical impact and cost-effectiveness. *PLoS One* 2010; 5(10): e13132.

2011

104. Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Papanizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes. *Blood* 2011 ; 117(23):6100-8.
105. Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S on behalf of FHDH-ANRS CO4. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a 3-drug regimen containing either efavirenz, nevirapine or abacavir. *J Antimicrob Chemoth* 2011; 66(8):1869-187.
106. Cain LE, Logan R, Robins JM, Sterne JAC, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernán MA. When to initiate combined antiretroviral therapy to reduce rates of mortality and AIDS in HIV-infected individuals in developed countries. *Ann Intern Med* 2011; 154(8): 509-515.
107. Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warszawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple class virologic failure in HIV-infected children. *Lancet* 2011; 377(9777): 1580-7.
108. Funk MJ, Fusco JS, Cole SR, Thomas JC, Porter K, Kaufman JS, Davidian M, White AD, Hartmann KE, Eron JJ. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. *Arch Intern Med.* 2011;171(17):1560-1569.
109. Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR; on behalf of the CASCADE Collaboration. Immune reconstitution and risk of kaposi sarcoma and nonhodgkin lymphoma in HIV-infected adults. *AIDS* 2011 ; 25(11):1395-403.
110. Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, Costagliola D, Gasnault J, on behalf the FHDH-ANRS CO4. Survival after neuroAIDS: association with antiretroviral CNS penetration-effectiveness score. *Neurology* 2011; 76: 644-651.
111. Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert J. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. *Blood* 2011; 118(1):44-49.

112. Lanoy E, Spano JP, Bonnet F, Guiguet M, Boué F, Cadranet J, Carcelain G, Couderc LJ, Frange P, Girard PM, Oksenhendler E, Poizot-Martin I, Semaille C, Agut A, Katlama C, Costagliola D and the ONCOVIH study group: The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. *Int J cancer* 2011; 129(2): 467-475.
113. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaud R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; on behalf of the CASCADE Collaboration in EuroCoord. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm³: Assessment of need following changes in treatment guidelines. *Clin Infect Dis* 2011; 53(8): 817-825.
114. Mugavero MJ, May M, Ribaud HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; on behalf of the AIDS Clinical Trial Group DACS 241 team AIDS Clinical Trial Group Study 5095 team AIDS Clinical Trial Group Study 5142 team and the Antiretroviral Cohort Collaboration. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study. *J Acquir Immune Defic Syndr* 2011; 58(3):253-260.
115. Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucchi M; on behalf of CASCADE Collaboration. Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. *AIDS* 2011; 25(8): 1041-1049.
116. van der Helm JJ, Prins M, Del Amo J, Bucher HC, Chêne G, Dorrucchi M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB; on behalf of the CASCADE Collaboration. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. *AIDS* 2011; 25(8): 1083-1091.

2012

117. del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Perez-Hoyos S, Jarrin I, Phillips A, Lodi S, van Sighem A, de Wolf F, Sabin C, Bansi L, Justice A, Goulet J, Miro JM, Ferrer E, Meyer L, Seng R, Touloumi G, Gargalianos P, Costagliola D, Abgrall S, Hernan MA and The HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. *Clin Infect Dis* 2012; 54(9): 1364-72.
118. Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Amy Justice A, Tate J, Logan R, James M. Robins JM, Sterne JAC, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Giorgia Vourli G, Anna EsteveA, Jordi Casabona J, Julia del Amo J, Santiago Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA and the HIV-CAUSAL Collaboration. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. *AIDS* 2012; 26(13):1691-1705.
119. Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczek D, Amanda Mocroft A, Dorrucchi M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosh J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Trends over calendar time in virological and clinical outcomes in individuals with HIV-1 infection and virologic failure of drugs from three antiretroviral drug classes: a cohort study. *Lancet Infect Dis* 2012; 12(2): 119 - 127.
120. Guiguet M, Ghosh J, Duvivier C, Meynard JL, Gras G, Partisani ML, Teicher E, Mahamat A, Rodembourg F, Launay O, Costagliola D, on behalf of the FHDH-ANRS CO4. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study in the FHDH-ANRS CO4 cohort. *AIDS* 2012; 26(18): 2345-2350.
121. Jarrin I, Pantazis N, Gill J, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, García de Olalla P, Porter K, del Amo J; CASCADE Collaboration in EuroCoord. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. *Clin Infect Dis* 2012; 54(1):111-8.

122. Jarzebowski W, Caumes E, Dupin N, Farhi D, Lascaux AS, Piketty C, de Truchis P, Bouldouyre MA, Derradji O, Pacanowski J, Costagliola D, Grabar S for the FHDH (ANRS CO4) study team. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: Results from the FHDH-ANRS CO4 cohort. *Arch Intern Med* 2012; 172(16):1237-1243.
123. Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccara F, Costagliola D, for the French Hospital Database on HIV-ANRS CO4. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. *Clin Infect Dis* 2012; 55(4):600–7.
124. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G, Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4 \geq 500/mm³ compared with the general population: evidence from a large European observational cohort collaboration. *Int J Epidemiol* 2012; 41(2): 433-45.
125. Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. *Arch Intern Med.* 2012; 172(16):1252-1255.
126. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaud R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. *Int J Epidemiol* 2012; 41(6): 1807-20.
127. Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J; for the Antiretroviral Therapy Cohort Collaboration (ART-CC). The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. *HIV Med.* 2012; 13(2): 89-97.
128. Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczar D, Mocroft A, Ledergerber B, Dorrucchi M, Cozzi-Lepri A, Jansen K, Masquelier B, Garcia F, De Wit S, Stephan C, Niels Obel N, Fätkenheuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe. *J Acquir Immune Defic Syndr* 2012; 59(3):294-9.
129. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. *PLoS One.* 2012; 7(3):e32369.
130. Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Grabar S. The incidence of HIV-related anal cancer remains elevated despite long-term cART: Results from the French Hospital Database on HIV (FHDH-ANRS CO4 cohort). *J Clin Oncol* 2012; 30(35): 4360-66.
131. Young J, Psychogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer HJ, Castagna A, De Wit S, Munoz J, Kjaer J, Colin C, Grarup J, Chene G, Bucher H and The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. *PLoS Med* 2012; 9(3):e1001194.
132. Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; the CASCADE Collaboration in EuroCoord. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. *Antivir Ther.* 2012; 17(6): 1039-1048.

2013

133. Abgrall S, Ingle SM, May MT, Cornish R, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Sirvent JLG, Sterne JAC, Antiretroviral Cohort Collaboration. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and N.America 2002-2009. *AIDS* 2013; 27(5) : 803–813.
134. del Amo J, Jarrin I, May M, Dabis F, Crane H, Podzamczar D, R Sterling TR, Abgrall S, Lampe F, Justice A, Castagna A, Boesecke C, Staehelin C, de Wolf F, Guest J, Mugavero MJ, Khaykin P, Samji H, Ingle S, Sterne JAC and M John Gill JM, Antiretroviral Therapy Cohort Collaboration (ART-CC). Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe and the United States. *Clin Infect Dis* 2013; 56(12):1800-9.
135. Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Costagliola D, Grabar S; on behalf of the FHDH-ANRS CO4 cohort. Risk of AIDS-defining cancers among HIV1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort. *Clin Infect Dis*. 2013; 57(11):1638-47.
136. Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; on behalf of the Beijing PRIMO cohort study and the CASCADE Collaboration in EuroCoord. Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. *J Acquir Immune Defic Syndr* 2013; 62(4):441-6.
137. Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, Grabar S, Mocroft A, Vilaro J, van Sighem A, Moreno S, Dabis F, Monforte AD, Teira R, Ingle SM, Sterne JA; Writing committee for the Antiretroviral Cohort Collaboration. Insurability of HIV positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. *AIDS* 2013; 27(10):1641-55.
138. Lacombe JM, Boue F, Grabar S, Viget N, Gazonas S, Lascaux-Cametz AS, Pacanowski J, Partisani M, Launay O, Matheron S, Rosenthal E, Rouveix E, Tattevin P, de Truchis P, Costagliola D, Goedert JJ. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. *AIDS* 2013; 27(4): 635-643.
139. Lederberger B, Costagliola D, Lodwick R, Torti C, van Sighem A, Podzamczar D, Mocroft A, Dorrucci M, Masquelier B, Günthard HF, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Chrysos G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Predictors of CD4 cell counts of HIV-1 - infected persons after virologic failure to all three original antiretroviral drug classes. *J Infect Dis* 2013; 207(5): 759-67.
140. Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E on behalf of the CASCADE collaboration in EuroCoord. Risk of tuberculosis following HIV seroconversion in high-income countries. *Thorax* 2013;68(3):207-13.
141. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K; for CASCADE Collaboration in EuroCoord. Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. *PLoS One*. 2013; 8(11): e78642.
142. Madec Y, Boufassa F, Porter K, Prins M, Sabin C, Monforte AD, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; on behalf of the CASCADE Collaboration in EuroCoord. Natural History of HIV control since seroconversion. *AIDS* 2013; 27(15):2451-60.
143. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; for the Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The Incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 Cells/ μ L in the post-combination antiretroviral therapy era. *Clin Infect Dis* 2013; 57(7):1038-47.

144. Mocroft A, Lundgren JD, Sabin ML, d'Arminio Monforte A, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Catherine C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O for the Late Presenters Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe study (COHERE) in EuroCoord. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). *PLoS Med.* 2013; 10(9):e1001510.
145. Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, Fde Salvador F, Launay O, Martinez V, Partisani M, Pradier C, Rouveix E, Valin N, Grabar S, Costagliola D on behalf of the FHDH ANRS CO4 cohort. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). *J Acquir Immune Defic Syndr* 2013; 64(2):197-203.
146. Sáez-Ciri6n A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guernon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C for the ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI study. *Plos Path* 2013; 9(3):e1003211.
147. Shepherd BS, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaylin P, Lehmann C, Ingle SM, May MT, Sterne JAC, Sterling TR, Antiretroviral Therapy Cohort Collaboration (ART-CC). Higher rates of AIDS during the first year of therapy among migrants: the importance of tuberculosis. *AIDS* 2013; 27(8):1321-9.
148. van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Ch6ne G, Dorrucchi M, Muga R, Porter K, Prins M; CASCADE Collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. *Gastroenterology* 2013; 144(4): 751-60.

2014

149. Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PCK, Fox MP, Gandhi NR, Gonz6lez E, Lee CKC, Hoffmann CJ, Kambugum A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio-Monforte A, P Luz PM, Chen YMA, Minga A, Casabona J, Mwangi A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M, the IeDEA and ART Cohort Collaborations. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries. *J Acquir Immune Defic Syndr* 2014; 65(1):e8-e16.
150. Boufassa F, Le Chenadec J, Meyer L, Costagliola D, Hunt PW, Florencia Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte L for the ANRS CO18 HIV Controllers Cohort, the Cascade Collaboration in EuroCoord, the SCOPE Cohort and the International HIV Controllers Study. Blunted response to combination antiretroviral therapy in HIV elite controllers: An international HIV controller collaboration. *Plos One* 2014; 17; 9(1): e85516.
151. Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JAC. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. *Plos Med* 2014; 11(9): e1001718.
152. Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro J, Podzamczar D, Olson A, Arribas J, Moreno S, Meyer L, del Romero J, Dabis F, Bucher H, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hern6n M. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurological conditions. *Neurology* 2014; 83(2):134-41.

153. Denis B, Guiguet M, de Castro N, Mechaï F, Revest M, Mahamat A, Melica Gregoire G, Lortholary O, Costagliola D. Critical importance of long term adherence to care in HIV infected patients in the cART era: new insights from *Pneumocystis jirovecii* pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort. *Plos One* 2014; 9(4):e94183.
154. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, Monforte AD, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; The Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV positive individuals virally suppressed for more than three years with incomplete CD4 recovery. *Clin Infect Dis* 2014; 58(9):1312-21.
155. Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, de Castro N, Berger JL, Dupont C, Lavole A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S. Risk of non AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from the FHDH-ANRS CO4 cohort. *AIDS* 2014; 28(14):2109-18.
156. Ingle SM, May MT, M. Gill J, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JAC for the Antiretroviral Therapy Cohort Collaboration. Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. *Clin Infect Dis.* (2014) 59 (2): 287-297.
157. Lang S, Mary-Krause M, Partisani M, Gilquin J, Simon A, Cotte L, Boccara F, Costagliola D, for the French Hospital Database on HIV-ANRS CO4. Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals? *AIDS* 2014; 28(13): 1987-89.
158. Lodi S, del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Olson A, van Sighem A, Reiss P, Sabin C, Jose S, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Vourli G, Antoniadou A, Dabis F, Vandenhede M, Costagliola D, Abgrall S, Hernán MA, the HIV-CAUSAL Collaboration. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. *AIDS.* 2014; 28(16): 2461-73.
159. Mary-Krause M, Grabar S, Lièvre L, Abgrall S, Billaud E, Boué F, Boyer L, Cabié A, Cotte L, De Truchis P, Duval X, Duvivier C, Enel P, Gasnault J, Gaud C, Gilquin J, Guiguet M, Katlama C, Khuong MA, Lacombe JM, Lang S, Lascaux AS, Launay O, Mahamat A, Matheron S, Meynard JL, Pavie J, Pilorgé F, Piroth L, Poizot-Martin I, Potard V, Pradier C, Reynes J, Rouveix E, Selinger-Leneman H, Simon A, Tattevin P, Tissot-Dupont H, Viard JP, Viget N, Costagliola D. Cohort profile: French Hospital Database on HIV (FHDH-ANRS CO4). *Int J Epidemiol* 2014;43(5):1425-36.
160. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe F, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill JM, Kitahata M, Saag MS, Guest J, Brodt HR, Sterne JAC. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). *Int J Epidemiol* 2014; 43(3):691-702.
161. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, Georget A, Aouba A, Rosenthal E, May T, Chauveau M, Diallo B, Costagliola D, Chene G; for the ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS* 2014; 28(8):1181-91.
162. The Natural History Project Writing Group for Collaboration of Observational HIV Epidemiological Research In Europe (COHERE) in EuroCoord: Nakagawa F, Lodwick R, Smith C, Costagliola D, van Sighem A, Ledergerber B, d'Arminio Monforte A, Dorrucchi M, Torti C, Suarez-Lozano I, Obel N, Brockmeyer N, Thiebaut R, Lundgren J, Castagna A, Alejos B, De Wit S, Zangerle R, Pantazis N, Ehren K, Casabona J, Grarup J, Chêne G, Phillips A. Factors associated with short-term changes in HIV viral load and CD4 cell count in antiretroviral-naïve individuals. *AIDS* 2014; 28(9):1351-6.

163. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Kholoud P for CASCADE Collaboration in EuroCoord. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. *PLOS One* 2014; 9(1):e86719.
164. Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucchi M, Johnson A, Sannes M, Moreno S, Porter K. Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype. *J Acquir Immune Defic Syndr* 2014; 67(1): 15-21.
165. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson A, Kelleher AD, Morrison C, Thiebaut R, Wittkop L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility. An observational cohort study. *Lancet HIV* 2014;1(3):e119-126.
166. Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D on behalf of FHDH ANRS CO4. Lopinavir/r no longer recommended as first line regimen: a comparative effectiveness analysis. *J Int AIDS Soc* 2014; 17(1): 19070.
167. van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunesheimer-Bartmeyer B, d'Arminio Monforte A, Olson A, Touloumi G, Sabin C, Porter K, Prins M, on behalf of CASCADE Collaboration in EuroCoord. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. *Lancet HIV* 2014; 1(1):e41-e48.

2015

168. Abgrall S, Rachas A, Tourret J, Isnard-Bagnis C, Billaud E, Tattevin P, Costagliola D, Guiguet M, Durieux P, on behalf of FHDH-ANRS CO4. A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease in HIV-infected patients: a cluster randomised trial. *Clin Infect Dis* 2015; 61(3):375-84.
169. Bruyand M, Le Marec F, Lavolé A, Leffondre K, Spano J-P, Le Moing V, Tattevin P, March L, Cadranet J, Bonnet F, Guiguet M. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients. *AIDS* 2015; 29(9): 1105–9.
170. Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, Semaille C. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. *Liver Int* 2015; 35(1): 65-70.
171. Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JAC, van Sighem A, Reiss P, Bucher HC, Fehr J, Touloumi G, Papanizos V, Esteve A, Casabona J, Monge S, Moreno S, R, Meyer L, Pérez-HoyosS, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán MA Boosted lopinavir versus boosted atazanavir-containing regimens and immunologic, virologic and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis* 2015; 60(8):1262-8.
172. Champredon D, Bellan SE, Delva W, Hunt S, Shi CF, Smieja M, Dushoff J. The effect of sexually transmitted co-infections on HIV viral load amongst individuals on antiretroviral therapy: a systematic review and meta-analysis. *BMC Infect Dis*. 2015;15:249.
173. Delaugerre C*, Ghosn J*, Lacombe JM, Pialoux G, Cuzin L, Launay O, Menard A, De Truchis P, Costagliola D for the FHDH-ANRS CO4. Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access. *Clin Infect Dis* 2015; 60 (3): 463-472.

*co-primary authors

174. Denis B, Guiguet M, de Castro N, Mechaï F, Revest M, Melica G, Costagliola D, Lortholary O on behalf of FHDH ANRS-CO4. Relevance of EORTC criteria for the diagnosis of invasive aspergillosis (IA) in HIV-infected patients, and survival trends over a 20-year period in France. *Clin Infect Dis* 2015; 61(8): 1273-1280.
175. Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, de Truchis P, Rabaud C, Rey D, Daneluzzi V, Ferret S, Lascaux AS, Hanslik T, Costagliola D, Launay O. Incidence of Herpes Zoster in HIV-Infected Adults in the Combined Antiretroviral Treatment (cART) Era: Results from the FHDH-ANRS CO4 Cohort. *Clin Infect Dis* 2015; 60(8):1269-77.
176. Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d'Arminio A, Cavassini M, Smith C, Justice AC, Gill MJ, Sterne JAC, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America: ART-CC. *AIDS* 2015;29(2):221-229.

177. Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavole A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S on behalf of FHDH-ANRS CO4. Trends in survival after cancer diagnosis among HIV-Infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 Cohort. *Int J Cancer* 2015; 137(10), 2443–2453.
178. Jarrin I, Moreno S, Ingle S, May MT, Sterling TR, Justice A, Bickel M, Crane H, Mugavero MJ, De Wolf F, Jung N, Cescon A, Garcia I, Elzi L, d'Arminio A, Mary-Krause M, Smith C, Guest J, Hessamfar M, Gill J, Sterne JAC, del Amo J for The Antiretroviral Therapy Cohort Collaboration (ART-CC). Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US. *Antivir Ther* 2015; 20(1):21-28.
179. Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa B, Costagliola D, Porter K, Blanco J, Del Amo J, Martinez-Picado J, for CASCADE Collaboration in EuroCoord. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved? *AIDS* 2015; 29(17):2323-2333.
180. Lang S, Lacombe JM, Mary-Krause M, Partisani M, Bidegain F, Cotte L, Aslangul A, Cheret A, Boccara F, Meynard JL, Pradier C, Roger PM, Pierre Tattevin P, Costagliola D, Molina JM, on behalf of the French Hospital Database on HIV. Is impact of statin therapy on all-cause mortality different in HIV-infected individuals compared to general population? Results from the FHDH-ANRS CO4 cohort. *Plos One* 2015; 10(7):e0133358.
181. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Miguel A Hernán MA, HIV-CAUSAL Collaboration. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV* 2015; 2(8):e335-343.
182. Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M; for the Efavirenz, Obesity Project Team the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naïve adults. *AIDS* 2015;29(2):193-200.
183. May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte AD, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection drug use and Hepatitis C as risk factors for mortality in HIV-infected individuals: the Antiretroviral Therapy Cohort Collaboration. *J Acquir Immune Defic Syndr* 2015; 69(3):348-54.
184. Mocroft A, Lundgren J, Antinori A, d'Arminio Monforte A, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Lepout C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O. Late presentation for HIV across Europe: An update from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) in EuroCoord. *Eurosurveillance* 2015; 20(47).
185. The Migrants Working Group on behalf of COHERE in EuroCoord, Monge S, Jarrín I, Mocroft A, Sabin CA, Touloumi G, van Sighem A, Abgrall S, Dray-Spira R, Spire B, Castagna A, Mussini C, Zangerle R, Hessamfar M, Anderson J, Hamouda O, Ehren K, Obel N, Kirk O, de Monteynard LA, Antinori A, Girardi E, Saracino A, Calmy A, De Wit S, Wittkop L, Bucher HC, Montoliu A, Raben D, Prins M, Meyer L, Chene G, Burns F, Del Amo J. Mortality in migrants living with HIV in western Europe (1997 - 2013): an collaborative cohort study. *Lancet HIV* 2015, 2(12): e540-e549.
186. de Monteynard LA, Dray-Spira R, De Truchis P, Grabar S, Launay O, Meynard JL, Khuong-Josses MA, Gilquin J, Rey D, Simon A, Pavie J, Mahamat A, Matheron S, Costagliola D, Abgrall S, on behalf of the French Hospital Database on HIV. Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France. *Plos One* 2015; 10(3):e0118492.
187. Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y, Costagliola D on behalf of FHDH ANRS CO4. Durability and effectiveness of maraviroc-containing regimens in HIV-1-infected individuals with virological failure in routine clinical practice. *Plos One* 2015; 10(12):e0144746.

188. Pourcher G, Costagliola D, Martinez V. Obesity in HIV-infected patients in France: Prevalence and surgical treatment options. *J Visc Surg* 2015; 152(1):33-7.
189. Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, Gueit I, Mortier E, Costagliola D, Morlat P, Chêne G, Cacoub P; the Mortalité 2010 and GERMIVIC study groups. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. *HIV Med* 2015; 16(4):230-239.
190. Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, Gill MJ, Schwarze-Zander C, Hernandez-Novoa B, Obel N, Kirk O, Abgrall S, Guest J, Samji H, D'Arminio Monforte A, Llibre JM, Smith C, Cavassini M, Burkholder GA, Shepherd B, Crane HM, Sterne J, Morlat P. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. *AIDS* 2015; 29(3):373-383.
191. Vandenhende MA, Roussillon C, Henard S, Morlat P, Georget A, May T, Rosenthal E, Salmon D, Cacoub P, Costagliola D, Chene G, Bonnet F for the ANRS EN20 Mortalité 2010 study group. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000. *Plos One* 2015; 10(6):e0129550.

2016

192. Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Papanizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz vs. boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-positive individuals. *Medicine* 2016; 95(41):e5133.
193. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill JM, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodriguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Perez-Hoyos S, Jarrin I, Guest JL, D'Arminio Monforte A, Antinori A, Moore R, Campbell CNJ, Casabona J, Meyer L, Seng S, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JAC, Hernan MA on behalf of the Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration. Using observational data to emulate a randomized trial of dynamic treatment switching strategies: an application to antiretroviral therapy. *Int J epidemiol* 2016; 45(6): 2038-2049.
194. Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice A, Tate J, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA; The Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. When to monitor CD4 cell count and HIV RNA to reduce mortality and AIDS-defining illness in virologically suppressed HIV-positive persons on antiretroviral therapy in high-income countries: a prospective observational study. *J Acquir Immune Defic Syndr* 2016; 72(2):214-21.
195. May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd L, Crane H, d'Arminio A, Burkholder G, Johnson M, Sobrino P, Domingo P, Zangerle R, Justice AC, Sterling T, Miro J, Sterne JA; Writing committee: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Mortality according to CD4 count at start of combination antiretroviral therapy among HIV positive patients followed for up to 15 years after start of treatment: collaborative cohort study. *Clin Infect Dis* 2016; 62(12):1571-7.
196. de Monteynard LA, Matheron S, Gilquin J, Pavie J, de Truchis P, Grabar S, Launay O, Meynard JL, Khuong-Josses MA, Rey D, Simon A, Mahamat A, Dray-Spira R, Costagliola D, Abgrall S. Influence of geographic origin, sex and HIV transmission group on the outcome of first line combined antiretroviral therapy (cART) in France. *AIDS* 2016; 30(14):2235-46.
197. Olson AD, Walker AS, Suthar AB, Sabin C, Bucher HC, Jarrin I, Moreno S, Perez-Hoyos S, Porter K, Ford D on behalf of CASCADE Collaboration in EuroCoord. Limiting cumulative HIV viremia copy years by early treatment reduces risk of AIDS and death. *J Acquir Immune Defic Syndr* 2016; 73(1):100-8.

198. Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher T, Lutsar I, Chaix ML, Fisher M, Moreno S, Porter K on behalf of CASCADE Collaboration in EuroCoord. The impact of short-course cART in primary HIV infection on viral suppression and immunologic response in later treatment. *AIDS* 2016; 30(6): 879-88.
199. Potard V, Simon A, Lacombe JM, Parienti JJ, Costagliola D on behalf of FHDH ANRS CO4. Switching to raltegravir from a virologically effective boosted protease inhibitor regimen: a comparative effectiveness analysis from the French Hospital Database on HIV (FHDH-ANRS CO4). *Clin Infect Dis* 2016; 63(9):1254-1261.
200. Rohner E, Schmidlin K, Zwahlen M, Chakraborty R, Clifford G, Obel N, Grabar S, Verbon A, Noguera-Julian A, Judd A, Collins IJ, Rojo P, Brockmeyer N, Campbell M, Chene G, Prozesky H, Eley B, Stefan DC, Davidson A, Chimbetete C, Sawry S, Davies MA, Kariminia A, Vibol U, Sohn A, Egger M, Bohlius J for The Pediatric AIDS-defining Cancer Project Working Group for leDEA Southern Africa, TAHOD and COHERE in EuroCoord. Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy from sub-Saharan Africa, Europe and Asia. *Clin Infect Dis* 2016;63(9):1245-1253.
201. Supervie V, Marty L, Lacombe JM, Dray-Spira R, Costagliola D and the FHDH-ANRS CO4 study group. Looking beyond the cascade of HIV care to end the AIDS epidemic: estimation of the time interval from HIV infection to viral suppression. *J Acquir Immune Defic Syndr* 2016; 73(3): 348-355.
202. Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, d'Arminio Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC). Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. *Plos One* 2016; 11(8):e0160460.
203. Wyss N, Zwahlen M, Clifford G, Campbell M, Chakraborty R, Bonnet F, Chene G, Bani-Sadr F, Verbon A, Zangerle R, Papanizos V, Prins M, Drona F, Le Moing V, Antinori A, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Vehreschild J, Obel N, Mocroft A, Brockmeyer N, Boue F, Sabin C, Spagnuolo V, Hasse B, De Wit S, Roca B, Egger M, Bohlius J for the Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Changing incidence and risk factors for Kaposi sarcoma by time since starting antiretroviral therapy: Collaborative analysis of 21 European cohort studies. *Clin Infect Dis* 2016; 63(10):1373-1379.

2017

204. Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d'Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, Battagay M, Brockmeyer N, Berenguer J, Morlat P, Obel N, De Wit S, Fätkenheuer G, Zangerle R, Ghosn J, Pérez-Hoyos S, Campbell M, Prins M, Chêne G, Meyer L, Dorrucci M, Torti C, Thiébaud R; Standard reference distribution of CD4 response to HAART project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. *HIV Med.* 2017; 18(1):33-44.
205. Caby F, Mary-Krause M, Duval X, Guiguet M, Boue F, Gallien S, Genet P, Gras G, Odile Launay O, Le Loup G, Lelievre JD, Moreau J, Tattevin P, Teicher E, Zucman D, Weiss L, Grabar S, Costagliola D, on behalf of FHDH-ANRS CO4. CD4/CD8 ratio restoration in long-term treated HIV-1-infected individuals: Incidence and determinants. *AIDS* 31(12):1685–1695.
206. Caniglia EC, Cain LE, Sabin C, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Gill J, Pacheco A, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Sterne JA, Costagliola D, Saag M, Hernán MA. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed HIV-positive individuals on combination antiretroviral therapy in high income countries: a prospective, observational study. *Lancet HIV* 2017; 4(6):e251-e259.

207. Chêne G, Phillips A, Costagliola D, Sterne J, Furrer H, del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbøl Brandt R, Friis-Moller N, Raben D, Haerry D, Egger M, Weller I, De Wit S for Cohere in EUrocoord. Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. *Int J Epidemiol* 2017; 46(3): 797-797n.
208. Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, Hamouda O, Estrada Perez V, Leal M, Mocroft A, Garcia De Olalla P, Ammassari A, D'Arminio Monforte A, Mussini C, Segura F, Castagna A, Cavassini M, Grabar S, Morlat P, De Wit S, Lambotte O, Meyer L1, HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. *PLoS One*. 2017; 12(4):e0173893.
209. Gourlay A, Noori T, Pharris A, Axelsson M, Costagliola D, Cowan S, Croxford S, d'Arminio Monforte A, del Amo J, Delpech V, Díaz A, Girardi E, Gunsenheimer-Bartmeyer B, Hernando V, Jose S, Leierer G, Nikolopoulos G, Obel N, Op de Coul E, Paraskeva D, Reiss P, Sabin C, Sasse A, Schmid D, Sonnerborg A, Spina A, Suligoi B, Supervie V, Touloumi T, Van Beckhoven D, van Sighem A, Vourli G, Zangerle R, Porter K and the European HIV continuum of care working group. The HIV continuum of care in European Union countries in 2013: data and challenges. *Clin Infect Dis* 2017; 64(12):1644-1656.
210. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. *Plos One* 2017; 12(10):e0184441.
211. Judd A, Lodwick R, Noguera-Julian A, Gibb D, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczar D, Dorrucchi M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer N, Warszawski J, Gonzalez Tome M, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A, the Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Higher rates of triple class virologic failure in perinatally HIV-infected teenagers compared to heterosexually infected young adults in Europe. *HIV Med* 2017; 18(3): 171-180.
212. Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco R, Hernando V, Bucher HC, Kovari H, Ferran Segura KH, Ambrosioni J, Gogos CA, Pantazis N, Sterne J, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill J, Krentz H, Phillips A, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. *J Acquir Immune Defic Syndr* 2017; 76(3):311-318.
213. Lusivika-Nzinga C, Selinger-Leneman H, Grabar S, Costagliola D, Carrat F. Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. *BMC Med Res Methodol* 2017;17(1):160.
214. Mangal TD; UNAIDS Working Group on CD4 Progression and mortality amongst HIV seroconverters including the CASCADE Collaboration in EuroCoord. Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. *AIDS*. 2017 May 15;31(8):1073-1082.
215. Monge S, Jarrín I, Pantazis N, Mocroft A, Sabin CA, Touloumi G, van Sighem A, Abgrall S, Dray-Spira R, Spire B, Castagna A, Mussini C, Zangerle R, Hessamfar M, Anderson J, Hamouda O, Ehren K, Obel N, Kirk O, de Monteynard LA, Antinori A, Girardi E, Saracino A, Calmy A, De Wit S, Wittkop L, Bucher HC, Montoliu A, Raben D, Prins M, Meyer L, Chene G, Burns F, Del Amo J for The Migrant Health Working Group on behalf of COHERE in EuroCoord. Timing of cART initiation in Male and Female Migrants Living with HIV in Western Europe: an observational cohort study (1997 - 2013). *AIDS* 2017; 31(6):835–846,

216. The AIDS-defining Cancer Project Working Group for leDEA and COHERE in EuroCoord, Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Garone D, Moore RD, D'Souza G, Goedert JJ, Achenbach C, Gill MJ, Kitahata MM, Patel P, Silverberg MJ, Castilho J, McGowan C, Chen YMA, Law M, Taylor N, Papanizos V, Bonnet F, Verbon A, Fätkenheuer G, Post FA, Sabin C, Mocroft A, Moing V, Dronda F, Obel N, Grabar S, Spagnuolo V, Antinori A, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Raben D, Clifford GM, Franceschi S, Brockmeyer N, Chakraborty R, Egger M, Bohlius J. Comparison of Kaposi Sarcoma risk in HIV-positive adults across 5 continents: A multiregional multicohort study. *Clin Infect Dis* 2017 ; 65(8):1316–26.
217. Trickey A, May MT, Schommers P, Tate J, Ingle S, Guest J, Gill J, Zangerle R, Saag M, Reiss P, d'Arminio Monforte A, Johnson M, Lima V, Sterling T, Cavassini M, Wittkop L, Costagliola D, Sterne JAC. CD4:CD8 ratio and CD8 count as prognostic markers for mortality in HIV-positive patients on ART. *Clin Infect Dis* 2017;65(6):959-966.
218. Trickey A, May, MT, Vehreschild JJ, Obel N, Gill J, Crane HM, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, d'Arminio Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro JM, Ingle S, Sterne JAC. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. *Lancet HIV* 2017; 4(8):E349-E356.
219. Wittkop L, Arsandaux J, Treviño A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vézinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas N, Lambotte O, Shepherd L, Lepout C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Moeller N, Costagliola D, Thiébaud R, Chene G, Matheron S. CD4 cell count response to first-line combination antiretroviral treatment in HIV-2 compared to HIV-1 positive patients - A Multinational Multicohort European Study. *J Antimicrob Chemother* 2017; 72 (10): 2869-2878.

2018

220. The leDEA and COHERE Cohort Collaborations, Anderegg N, Panayidou K, Abo Y, Alejos B, Althoff KN, Anastos K, Antinori A, Balestre E, Becquet R, Castagna A, Castelnuevo B, Chêne G, Coelho L, Collins IJ, Costagliola D, Crabtree-Ramírez B, Dabis F, d'Arminio Monforte A, Davies MA, De Wit S, Delpech V, De La Mata NL, Duda S, Freeman A, Gange SJ, Grabmeier-Pfistershammer K, Günsenheimer-Bartmeyer B, Jiamsakul A, Kitahata MM, Law M, Manzardo C, McGowan C, Meyer L, Moore R, Mussini C, Nakigozi C, Nash D, Tek Ng O, Obel N, Pantazis N, Poda A, Raben D, Reiss P, Rikken L, Sabin C, Sinayobye J, Sönnnerborg A, Stoeckle M, Thorne C, Torti C, Twizere C, Wasmuth JC, Wittkop L, Wools-Kaloustian K, Yotebieng M, Kirk O, Egger M. Global trends in CD4 count at start of antiretroviral treatment: collaborative study of treatment programs. *Clin Infect Dis* 2018, 66(6):893-903.
221. Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. *J Acquir Immune Defic Syndr* 2018; 77(1):102-109.
222. Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, Gill J, Schommers P, Costagliola D, Guest JL, Lima VD, Monforte AD, Smith C, Cavassini M, Saag M, Sterling TR, Sterne JAC. Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio. *AIDS* 2018;32(10):1361-1367.
223. Jarrin I, Monge S, Mocroft A, Sabin CA, Touloumi G, van Sighem A, Abgrall S, Dray-Spira R, Spire B, Castagna A, Mussini C, Zangerle R, Hessamfar M, Anderson J, Hamouda O, de Monteynard LA, Antinori A, Girardi E, Saracino A, Calmy A, De Wit S, Wittkop L, Bucher HC, Montoliu A, Raben D, Prins M, Meyer L, Chene G, Burns F, Del Amo J for the Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? *HIV Medicine* 2018; 19(1):42-48.

224. Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, de Truchis P, Katlama C, Martin-Blondel G, Aurelia Henn A, Matthieu Revest M, Robineau O, Khuong-Josses M-A, Canestri A, De Castro N, Joly V, Mokhtari S, Risso K, Gasnault J*, Costagliola D*. Risk of Progressive multifocal leukoencephalopathy in the combined antiretroviral therapy era in the French hospital database on HIV (ANRS-C04). *Clin Infect Dis* 2018; 67(2):275-282.
225. de Monteynard LA, Matheron S, Grabar S, de Truchis P, Gilquin J, Pavie J, Launay O, Meynard JL, Khuong-Josses MA, Rey D, Aba Mahamat A, Dray-Spira R, Simon A, Costagliola D, Abgrall S. Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. *Plos One* 2018; 13(10):e0205385.
226. Panayidou K, Davies MA, Anderegg N, Egger M, The IeDEA, COHERE, PHACS and IMPAACT 219C Collaborations Writing Group. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral-therapy in an era of changing criteria for treatment initiation. *JIAS* 2018; 21(11): e25200.
227. Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. *J Int AIDS Soc* 2018;21(1).
228. Potard V, Goujard C, Valantin MA, Lacombe JM, Lahoulou R, Chéret A, Girard PM, Costagliola D on behalf of the French Hospital Database on HIV (FHDH-ANRS CO4). Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens. *BMC Infect Dis* 2018;18:326.
229. Rohner E for the AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. Non-Hodgkin lymphoma risk in adults living with HIV across five continents: a multicohort study. *AIDS*; 2018; 32(18): 2777-2786.
230. Roul H, Mary-krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, Launay O, Lacombe JM, Menard A, De Truchis P, Delfraissy JF, Weiss L, Costagliola D. CD4 cell count recovery after combined antiretroviral therapy in the modern cART era. *AIDS* 2018; 32(17):2605-2614.
231. Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, Young J, Bucher HC, Babiker AG; CASCADE Collaboration in EuroCoord. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. *HIV Med* 2018; 19(3):184-194.

2019

232. Balde A, Lang S, Wagner A, Ferrieres J, Montaye M, Tattevin P, Cotte L, Aslangul E, Bidegain F, Cheret A, Mary-Krause M, Meynard JL, Partisani M, Roger PM, Boccara F, Costagliola D. Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status. *Plos One* 2019; 14(1):e0210253.
233. Caniglia ED, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro J, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: an application to monitoring and treatment of HIV-positive individuals. *Stat Med* 2019; 38(13):2428-2446..
234. Costagliola D, Potard V, Lang S, Abgrall S, Duvivier C, Fischer H, Joly V, Lacombe JM, Valantin MA, Mary-Krause M, Rozenberg S on behalf of FHDH ANRS CO4. Impact of antiretroviral drugs on fracture risk in HIV-infected individuals: A case-control study nested within the French Hospital Database on HIV (FHDH-ANRS CO4). *J Acquir Immune Defic Syndr* 2019; 80:214–223.
235. Grabar S, Hleyhel M , Belot A, Bouvier Am, Tattevin P, Pacanowski J, Genet P, Pradier C, Salmon D, Simon A, Pourcher V, Spano Jp, Poizot-Martin I, Costagliola D. Invasive cervical cancer in HIV-infected women: risk and survival relative to that of the general population in France. 2019; 20(3):222-229.

236. Gras L, May M, Ryder LP, Trickey A, Helleberg M, Obel N, Thiebaut R, Guest J, Gill J, Crane H, Lima VD, d'Arminio Monforte A, Sterling TR, Miro J, Moreno S, Stephan C, Smith C, Tate J, Shepherd L, Saag M, Rieger A, Gillor D, Cavassini M, Montero M, Ingle SM, Reiss P, Costagliola D, Wit FWNM, Sterne J, de Wolf F, Geskus R, for the Antiretroviral Therapy Cohort Collaboration (ART-CC). Determinants of Restoration of CD4 and CD8 Cell Counts and their Ratio in HIV-1 Positive Individuals with Sustained Virological Suppression on Antiretroviral Therapy. *J Acquir Immune Defic Syndr* 2019; 80(3):292-300.
237. Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA; INSIGHT START Study Group and the HIV-CAUSAL Collaboration Effect estimates in randomized trials and observational studies: comparing apples with apples. *Am J Epidemiol* 2019; 188(8):1569-1577.
238. Potard V, Gallien S, Canestri A, Costagliola D. Use of darunavir in HIV-1 infected individuals in routine clinical practice from 2012 to 2016 in France. *J Antimicrob Chemother* 2019; 74(11):3305-3314.
239. Tourret J, Guiguet M, Lassalle M, Grabar S, Lièvre L, Isnard-Bagnis C, Barrou B, Costagliola D, Couchoud C, Abgrall S, Tézenas Du Montcel S. Access to the waiting list and to kidney transplantation for people living with HIV: a national registry study. *Am J Transplant.* 2019; 19(12):3345-3355.
240. Trickey A, Van Sighem A, Stover J, Abgrall S, Grabar S, Bonnet F, Berenguer J, Wyen C, Casabona J, D'Armino Monforte A, Cavassini M, Del Amo J, Zangerle R, Gill J, Obel N, Sterne JAC, May MT. Parameter estimates for trends and patterns of excess mortality among persons on ART in high-income European settings. *AIDS* 2019; 15;33 Suppl 3:S271-S281.
241. Vourli G, Pharris A, Cazein F, Costagliola D, Dabis F, Del Amo J, Delpech V, Díaz A, Girardi E, Gourlay A, Gunsenheimer-Bartmeyer B, Hernando V, Nikolopoulos G, Porter K, Rosińska M, Sabin C, Suligoj B, Supervie V, Wit F, Touloumi G. Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population? *AIDS* 2019; 33(1):133-143.

2020

242. Besson C, Noe N, Lancar R, Prevot S, Algarte-Genin M, Rosenthal E, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Cheret A, Arvieux C, Katlama C, Salmon D, Boué F, Costello R, Hendel-Chavez H, Taoufik Y, Fontaine H, Coppo P, Mounier N, Delobel P, Costagliola D on behalf of the Lymphovir and FHDH Study Groups. HCV or HBV coinfection and lymphoma risk in people living with HIV. *AIDS* 2020; 34 (4), 599-608.
243. Caby F, Guiguet M, Weiss L, Winston A, Miro JM, Konopnicki D, Le Moing V, Bonnet F, Reiss P, Mussini C, Poizot-Martin I, Taylor N, Skoutelis A, Meyer L, Goujard C, Bartmeyer B, Boesecke C, Antinori A, Quiros-Roldan E, Wittkop L, Frederiksen C, Thurnheer MC, Svedhem V, Jose S, Costagliola D, Mary-Krause M, Grabar S. CD4/CD8 ratio and the risk of Kaposi sarcoma or non-Hodgkin lymphoma in the context of efficiently treated HIV infection: a collaborative analysis of 20 European cohort studies. *Clin Infect Dis* 2020.
244. Costagliola D, Potard V, Lang S, de Castro N, Cotte L, Duval X, Duvivier C, Grabar S, Mary-Krause M, Partisani M, Ronot-Bregigeon S, Simon A, Tattevin P, Weiss L, Zucman D, Katlama C, Raffi F, Boccara F on behalf of ANRS CO4 FHDH. Is the risk of myocardial infarction in PLHIV associated with atazanavir or darunavir? A nested case-control study within the French Hospital Database on HIV. *J Infect Dis* 2020; 221(4): 516-522.
245. Laut K, Antinori A, Bartmeyer B, Beniowski M, Bonnet F, Brännström J, Casabona J, Castagna C, Chene G, Costagliola D, d'Arminio Monforte A, del Amo J, De Wit S, Faetkenheuer G, Furrer H, Gasiorowski J, Jadand C, Kirk O, Lazanas MK, Suarez-Lozano I, Lundgren J, Mikhalik J, Mocroft A, Moreno S, Mussini C, Obel N, Paduta D, Raben D, Reiss P, Riordan A, Sabin CA, Smidt J, Torti C, Trofimova T, Vassilenko A, Vasylyev M, Warszawski J, Wittkop L, Yakovlev A, Zangerle R. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. *BMC Infect Dis* 2020.
246. Makinson A, Tron L, Grabar S, Milleron B, Reynes J, Le Moing V, Morquin D, Lert F, Costagliola D, Guiguet M, on behalf of the French Hospital Database on HIV (ANRS-CO4). Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French Hospital Database on HIV cohort. *HIV Medicine* 2020; 21 (3), 180-188.

247. Melliez H, Mary-Krause M, Guiguet M, Carrieri P, Abgrall S, Enel P, Gallien S, Duval X, Duvivier C, Pavie J, Siguier M, Freire-Maresca A, Tattevin P, Costagliola D. Risk of severe bacterial infection in people living with HIV infection in the cART era. *J Infect Dis* 2020; 222(5):765-776.
248. Potard V, Gallien S, Canestri A, Costagliola D. Use of rilpivirine in HIV-1 infected individuals in routine clinical practice from 2012 to 2017 in France *J Antimicrob Chemother* 2019; 74(11):3305-3314.
249. Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Pappas M, Bonnet F, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J. Cervical cancer risk in women living with HIV across four continents: A multicohort study. *Int J Cancer*; 2020; 146(3):601-609.
250. Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit FWNM, Bonnet F, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier-Pfistershammer K, Guest J, Shepherd L, Teira Ramon, d'Arminio Monforte A, del Amo J, Justice A, Costagliola D, Sterne J. Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies. *Int J cancer* 2020; 146(11):3134-3146.
251. Vourli G, Noori T, Pharris A, Porter K, Axelsson M, Begovac J, Cazein F, Costagliola D, Cowan S, Croxford S, d'Arminio Monforte A, Delpech V, Díaz A, Girardi E, Gunsenheimer-Bartmeyer B, Hernando V, Leierer G, Lot F, Nunez O, Obel N, Op de Coul E, Paraskeva D, Patrinos S, Reiss P, Schmid D, Sonnerborg A, Suligoi B, Supervie V, van Sighem A, Zangerle R, Touloumi G, and the European HIV continuum of care working group. HIV Continuum of Care in 11 EU countries at the end of 2016 overall and by key population: have we made progress? *Clin Infect Dis* 2020.

2021

252. Potard V, Gallien S, Canestri A, Costagliola D, French Hospital Database on HIV (FHDH-ANRS CO4). Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France. *J Antimicrob Chemother*. 19 janv 2021;76(2):467-76
253. Caby F, Guiguet M, Weiss L, Winston A, Miro JM, Konopnicki D, Le Moing V, Bonnet F, Reiss P, Mussini C, Poizot-Martin I, Taylor N, Skoutelis A, Meyer L, Goujard C, Bartmeyer B, Boesecke C, Antinori A, Quiros-Roldan E, Wittkop L, Frederiksen C, Thurnheer MC, Svedhem V, Jose S, Costagliola D, Mary-Krause M, Grabar S. CD4/CD8 ratio and the risk of Kaposi sarcoma or non-Hodgkin lymphoma in the context of efficiently treated HIV infection: a collaborative analysis of 20 European cohort studies. *Clin Infect Dis* 2021.
254. Castry M, Cousien A, Bellet J, Champenois K, Pialoux G, Yazdanpanah Y, Costagliola D, Grabar S, Deuffic-Burban S; for the French Hospital Database on HIV (ANRS CO4-FHDH Cohort). Hepatitis C virus incidence among men who have sex with men living with HIV in France: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014-2017. *Eurosurveillance* 2021.